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Regarding overall survival of refractory Small-cell lung cancer (SCLC) 
patients, long-term survival is quite uncommon, with less than 25% of patients with 
limited-stage, and 1-2 % of patients with extensive-stage disease remaining alive at 5 
years. Recent clinical studies demonstrated the promising efficacy of amrubicin for 
patients with relapsed SCLC, and this review presents the results of clinical studies 
showing the efficacy and safety of amrubicin for the treatment of relapsed SCLC. 
Amrubicin is a completely synthetic anthracycline agent with a similar structure to 
doxorubicin, in which the hydroxyl group at position 9 is replaced by an amino group in 
amrubicin to enhance efficacy. It is converted to an active metabolite, amrubicinol, 
which is 5-54 times more active than amrubicine. Amrubicine and amrubicinol are 
inhibitors of DNA topoisomerase II, developing their cytotoxic effects by stabilizing a 
topoisomerase II-mediated cleavable complex. Toxicities of amrubicin are similar to 
that of doxorubicin, however, amrubicin shows almost no cardiotoxicity. Amrubicin 
was administered intravenously at a dose of 35-40 mg/m2 on days 1 to 3 every 3 weeks. 
The response rate was 34-52% and the median survival times were 8.1-12.0 months. 
Common adverse events were hematologic toxicities, including neutropenia, leucopenia, 
anemia, thrombocytopenia, and febrile neutropenia. Non-hematologic adverse events 
included grade 3-4 anorexia, asthenia, hyponatremia and nausea. The results of the 
studies which demonstrated the efficacy of monotherapy for relapsed SCLC involved 
mainly Japanese patients. Therefore, it is necessary to conduct clinical studies more in 
non-Japanese patients to confirm the amrubicin efficacy. 
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INTRODUCTION 
Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung 
cancer cases, with two thirds of patients presenting with extensive disease (ED). 
Without treatment, tumor progression in patients with SCLC is rapid, with a poor 
prognosis. Meanwhile, it shows a high response rate to chemotherapy and radiotherapy, 
except in a low percent of patients. Treatment options for relapsed SCLC patients 
remains limited. A randomized trial demonstrated that single-agent topotecan was at 
least as efficacious as the three-drug combination of cyclophosphamide, doxorubicin, 
and vincristin (CAV) for the treatment of patients with sensitive relapsed cases (1). 
Response rates and median survival times were 24%, and 25.0 weeks for topotecan, and 
18% and 24.7 weeks for CAV, respectively. In previously untreated ED-SCLC, 
amrubicin yielded an extremely high response rate of 79% and a median survival time 
(MST) of 11 months, which was comparable to the results of platinum (2, 3). Recently, 
clinical studies demonstrated the efficacy of amrubicin for patients with relapsed SCLC. 
This review presents the results of clinical studies showing the efficacy and safety of 
amrubicin for the treatment of relapsed SCLC.  
 
 
STRUCTURE AND CHARACTERISTICS 
Amrubicin hydrochloride is a completely synthetic anthracycline agent with a 
similar structure to doxorubicin, in which the hydroxyl group at position 9 is replaced 
by an amino group in amrubicin to enhance efficacy (Figure 1). Amrubicin is converted 
to an active metabolite, amrubicinol, which is 5-54 times more active than amrubicine, 
through reduction of its C-13 ketone group to a hydroxyl group by carbonyl reductase 
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(4). Other enzymes metabolizing amrubicin and amrubicinol are NADPH-dependent 
P450 reductase and NAD[P]H-dependent quinone oxidereductase. Doxorubicin, 
amrubicine and amrubicinol are inhibitors of DNA topoisomerase II, developing their 
cytotoxic effects by stabilizing a topoisomerase II-mediated cleavable complex (5). 
Additionally, they are more or less only one-tenth as potent as doxorubicin in producing 
DNA intercalation.  
 
PRECLINICAL STUDIES 
Antitumor activities and toxicological aspects were firstly reported by 
Morisada et al. They evaluated in six murine experimental tumor systems and nine 
human tumor-nude mouse systems, and anti-tumor activities of amrubicin were superior 
to adriamycin (ADR) against human tumor xenografts, and almost equal against murine 
experimental tumors (6). They also evaluated toxicities in mice after a bolus intravenous 
injection. The acute toxic signs were body weight decrease, ataxia, hair loss, and 
myelosuppression and these toxicities were qualitatively comparable to those induced 
by ADR. The maximum tolerated dose (MTD) for such administration was estimated to 
be 25 mg/kg in 4 mouse strains, and it has anticancer activity against human lung cancer 
xenografts in vivo (7).  
Cardiomyopathy is burdensome toxicity for anthracyclines. Suzuki et al 
evaluated the degree of cardiotoxicity of amrubicin compared with that of ADR in 
rabbits (8). Drugs were intravenously administered 3 times a week for 8 weeks. In the 
electrocardiogram study, prolongation of QTc interval and ST-T change were observed 
in rabbits administered amrubicin and ADR. Morphological studies showed that 
myocardial tissue damage in animals administered amrubicin was comparable to that in 
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the negative controls. Considering the results of antitumor efficacy studies comparing 
with ADR, they concluded the cardiotoxicity of amrubicin was very slight.  
 
RELAPSED SCLC 
Regarding overall survival of refractory SCLC patients, long-term survival is 
quite uncommon, with less than 25% of patients with limited-stage, and 1-2 % of 
patients with extensive-stage disease remaining alive at 5 years. A phase II study was 
conducted in patients with relapsed disease who had previously received one or two 
regimens, including at least one regimen of platinum-based chemotherapy (9) (Table 1). 
Sixty patients were enrolled in this multicenter trial. Sixteen and 44 patients, 
respectively, in refractory groups, in which the disease progressed within 60 days after 
the final dose of previous chemotherapy, and in sensitive groups, in which complete 
response (CR) or partial response (PR) was observed with previous chemotherapy and 
the disease then progressed or relapsed at least 60 days after the final dose of previous 
chemotherapy were eligible for the study, and were assessable for toxicity, response, 
and survival. Amrubicin was administered intravenously at a dose of 40 mg/m2 on days 
1 to 3 every 3 weeks. The response rate was 52% [95% CI: 38-65%]. There were no 
differences in the response rate between 50% [95% CI: 25-75%] for refractory disease 
and 52% [95% CI: 37-68%] for sensitive disease. The median survival times were 10.3 
months in the refractory group and 11.6 months in the sensitive group, respectively 
(p=0.0974; log rank test). Common adverse events were hematologic toxicities, 
including grade 3-4 neutropenia (83%), leucopenia (70%), anemia (33%), 
thrombocytopenia (20%), and febrile neutropenia (5%). Non-hematologic adverse 
events included grade 3-4 anorexia (15%), asthenia (15%), hyponatremia (8%) and 
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nausea (5%).  
Another phase II study of amrubicin in patients with previously treated SCLC 
was conducted by Kaira et al. (10) (Table 2). Twenty-nine patients with relapsed SCLC 
who had previously received platinum-based chemotherapy were enrolled in the trial of 
10 patients with sensitive relapse and 19 patients with refractory relapse. Amrubicin 
was administered intravenously at a dose of 35 mg/m2 on day 1 to 3 every 3 weeks. The 
response rate was 44.8% (95% CI: 26-64%): 60% for sensitive cases and 37% for 
refractory cases. No significant difference in the response rate was observed between 
sensitive cases and relapsed cases (p=0.233; log rank test). The median progression-free 
survival and median survival times were 4.0 months (sensitive relapse, 4.0 months; 
refractory relapse, 4.0 months) and 12.0 months (sensitive relapse, 12.0 months; 
refractory relapse, 11.0 months). There were no differenced in median progression-free 
survivals and median survival time between sensitive relapse and refractory relapse. 
Grade 3 or 4 neutropenia and febrile neutropenia were observed in 42% and 3%. 
Non-hematological toxicity more than grade 3 was not observed. The results of this 
study show the efficacy of monotherapy for relapsed SCLC; however, this study 
involved only Japanese patients, it is therefore necessary to conduct clinical studies in 
non-Japanese patients to confirm the efficacy.  
A randomized phase II trial of amrubivin versus topotecan as second-line 
treatment for sensitive ED-SCLC was therefore conducted (11) (Table 3). Seventy-six 
patients who had previously received platinum-based first-line chemotherapy were 
enrolled. All were sensitive cases, in which CR or PR had been observed with the 
previous chemotherapy and the disease had then progressed or relapsed at least 90 days 
after the final dose. Patients were randomized at a 2:1 ratio to receive either amrubicin 
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or topotecan. Amrubicin was administered intravenously at a dose of 40 mg/m2 on day 1 
to 3 every 3 weeks. Topotecan was administered intravenously at a dose of 1.5 mg/m2 
on day 1 to 5 every 3 weeks. The response rate of amrubicin was 34% [95% CI: 
22-48%], and topotecan was 4% [95% CI: 1-19%]. There was a trend toward a longer 
progression-free survival time in the amrubicin group (4.6 months, 95% CI: 64-187) 
than in the topotecan group (3.5 months, 95% CI: 75-177). This study showed that 
amrubicin is active in non-Japanese patients and is well tolerated, with myelotoxicity 
being the main dose-limiting toxicity. Sugawara et al. conducted a randomized phase II 
trial comparing amrubicin with topotecan in not only sensitive relapse but refractory 
cases (12) (Table 4). Sensitive cases were defined as CR or PR being achieved with the 
previous chemotherapy after which the disease progressed or relapsed at least 90 days 
after the final dose. Fifty-nine patients were randomized at a 1:1 ratio to receive either 
amrubicin or topotecan. Amrubicin was administered intravenously at a dose of 40 
mg/m2 on day 1 to 3 every 3 weeks. Topotecan was administered intravenously at a 
dose of 1.0 mg/m2 on day 1 to 5 every 3 weeks. The response rate of amrubicin was 
38% [95% CI: 60-92%], and topotecan was 13% [95% CI: 4-31%]. In sensitive relapsed 
cases, the response rate of amrubicin was 53% [95% CI: 28-77%], and topotecan was 
21% [95% CI: 6-46%]. In refractory relapsed cases, the response rate of amrubicin was 
17% [95% CI: 2-48%], and topotecan was 0% [95% CI: 0-28%]. The median 
progression-free survival with amrubicin was 3.5 months, and topotecan was 2.2 
months. The median overall survival with amrubicin was 8.1 months, and topotecan was 
8.4 months. There was no difference in the frequency of hematological toxicity more 
than grade 3 between amrubicin and topotecan. These studies showed that amrubicin 
monotherapy is an encouraging regimen for second-line treatment of SCLC.  
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CONCLUSION 
Clinical studies of the novel anticancer agent amrubicin have increased 
quickly, and there are high expectations for this agent in trials to improve the outcome 
for relapsed SCLC patients. Amrubicin is an active agent for the treatment of relapsed 
SCLC, but because it is strongly myelotoxic, particular care should be taken.  
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Table 1 Phase II trial of amrubicin for treatment of refractory or relapsed small cell lung cancer (Thoracic Oncology 
Research Group Study 0301) 
                                Sensitive case        Refractory case         Total 
No. of patients                     44                    16                   60 
CR                                1                     1                    2 
PR                               22                     7                    2 
SD                               10                     2                   12 
PD                               11                     6                   17 
Response rate (95% CI)              52% (37-68%)           50% (25-75%)          52% (38-65%) 
Progression-free survival (95% CI)     4.2 months (10.0-15.8)    2.9 months (1.4-4.6)    3.9 months (3.4-4.6) 
Median survival time (95% CI)         11.6 months (10.0-15.8)   10.3 months (4.8-∞)   11.0 months (10.0-13.2)




Table 2 Phase II trial of amrubicin for treatment of relapsed small cell lung cancer 
                                   Sensitive case       Refractory case      Total 
No. of patients                      10                  19                 29 
Response rate (95% CI)               60%                 37%                45% (26-64%) 
Progression-free survival             4.0 months           4.0 months          4.0 months 




Table 3 Randomized phase II trial of amrubicin vs topotecan for treatment of sensitive relapsed small cell lung 
cancer 
                                       Amrubicin              Topotecan              p. value 
No. of patients                              50                    26 
Overall response rate (95% CI)           34% (22.4-47.8%)         4% (0.7-18.9%)            < 0.004 
CR (95% CI)                            8% (3.2-18.8%)           0% 
PR (95% CI)                           26% (15.9-39.6)           4% (0.7-18.9%) 
SD (95% CI)                           32% (20.8-45.8%)         46% (28.8-64.5%) 
PD (95% CI)                           24% (14.3-37.4%)         23% (11.0-42.1%) 





Table 4 Randomized phase II trial comparing amrubicin with topotecan in patients with sensitive and refractory 
relapsed small cell lung cancer 
                                       Amrubicin              Topotecan              p. value 
No. of patients                              29                    30 
Overall response rate (95% CI)            38% (21-58%)            13% (2-31%)            = 0.039 
ORR* in sensitive cases (95% CI)           53% (28-77%)            21% (6-46%)            = 0.082 
ORR in refractory cases (95% CI)           67% (35-90%)            18% (2-52%)            = 0.478 
Median progression-free survival            3.5 months              2.2 months             = 0.16 
Overall survival                          8.1 months              8.4 months             = 0.17 
* Overall response rate 
 
